No Cover Image

Journal article 534 views 51 downloads

Using ChEMBL to Complement Schistosome Drug Discovery

Gilda Padalino Orcid Logo, Avril Coghlan, Giampaolo Pagliuca, Josephine E. Forde-Thomas Orcid Logo, Matthew Berriman Orcid Logo, Karl F. Hoffmann

Pharmaceutics, Volume: 15, Issue: 5, Start page: 1359

Swansea University Author: Gilda Padalino Orcid Logo

  • 64493.VOR.pdf

    PDF | Version of Record

    © 2023 by the authors. Licensee MDPI, Basel, Switzerland. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).

    Download (4.69MB)

Check full text

DOI (Published version): 10.3390/pharmaceutics15051359

Abstract

Schistosomiasis is one of the most important neglected tropical diseases. Until an effective vaccine is registered for use, the cornerstone of schistosomiasis control remains chemotherapy with praziquantel. The sustainability of this strategy is at substantial risk due to the possibility of praziqua...

Full description

Published in: Pharmaceutics
ISSN: 1999-4923
Published: MDPI AG 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa64493
first_indexed 2023-10-05T08:30:33Z
last_indexed 2024-11-25T14:14:07Z
id cronfa64493
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2024-01-08T14:13:05.6811311</datestamp><bib-version>v2</bib-version><id>64493</id><entry>2023-09-08</entry><title>Using ChEMBL to Complement Schistosome Drug Discovery</title><swanseaauthors><author><sid>7e5526209f02734f57ba19b0d17604ec</sid><ORCID>0000-0001-8580-1293</ORCID><firstname>Gilda</firstname><surname>Padalino</surname><name>Gilda Padalino</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-09-08</date><deptcode>MEDS</deptcode><abstract>Schistosomiasis is one of the most important neglected tropical diseases. Until an effective vaccine is registered for use, the cornerstone of schistosomiasis control remains chemotherapy with praziquantel. The sustainability of this strategy is at substantial risk due to the possibility of praziquantel insensitive/resistant schistosomes developing. Considerable time and effort could be saved in the schistosome drug discovery pipeline if available functional genomics, bioinformatics, cheminformatics and phenotypic resources are systematically leveraged. Our approach, described here, outlines how schistosome-specific resources/methodologies, coupled to the open-access drug discovery database ChEMBL, can be cooperatively used to accelerate early-stage, schistosome drug discovery efforts. Our process identified seven compounds (fimepinostat, trichostatin A, NVP-BEP800, luminespib, epoxomicin, CGP60474 and staurosporine) with ex vivo anti-schistosomula potencies in the sub-micromolar range. Three of those compounds (epoxomicin, CGP60474 and staurosporine) also demonstrated potent and fast-acting ex vivo effects on adult schistosomes and completely inhibited egg production. ChEMBL toxicity data were also leveraged to provide further support for progressing CGP60474 (as well as luminespib and TAE684) as a novel anti-schistosomal compound. As very few compounds are currently at the advanced stages of the anti-schistosomal pipeline, our approaches highlight a strategy by which new chemical matter can be identified and quickly progressed through preclinical development.</abstract><type>Journal Article</type><journal>Pharmaceutics</journal><volume>15</volume><journalNumber>5</journalNumber><paginationStart>1359</paginationStart><paginationEnd/><publisher>MDPI AG</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>1999-4923</issnElectronic><keywords>ChEMBL; schistosomiasis; drug discovery pipeline; schistosomula; adult worm; bioinformatics; cytotoxicity</keywords><publishedDay>28</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-04-28</publishedDate><doi>10.3390/pharmaceutics15051359</doi><url>http://dx.doi.org/10.3390/pharmaceutics15051359</url><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>This research was funded by the Wellcome Trust, grant number 107475/Z/15/Z.</funders><projectreference/><lastEdited>2024-01-08T14:13:05.6811311</lastEdited><Created>2023-09-08T15:56:05.8587393</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Pharmacy</level></path><authors><author><firstname>Gilda</firstname><surname>Padalino</surname><orcid>0000-0001-8580-1293</orcid><order>1</order></author><author><firstname>Avril</firstname><surname>Coghlan</surname><order>2</order></author><author><firstname>Giampaolo</firstname><surname>Pagliuca</surname><order>3</order></author><author><firstname>Josephine E.</firstname><surname>Forde-Thomas</surname><orcid>0000-0002-7202-3565</orcid><order>4</order></author><author><firstname>Matthew</firstname><surname>Berriman</surname><orcid>0000-0002-9581-0377</orcid><order>5</order></author><author><firstname>Karl F.</firstname><surname>Hoffmann</surname><order>6</order></author></authors><documents><document><filename>64493__28710__0bd622d79e6d462e93a9d9bf1ee697de.pdf</filename><originalFilename>64493.VOR.pdf</originalFilename><uploaded>2023-10-05T09:30:48.7730596</uploaded><type>Output</type><contentLength>4917749</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2023 by the authors. Licensee MDPI, Basel, Switzerland. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2024-01-08T14:13:05.6811311 v2 64493 2023-09-08 Using ChEMBL to Complement Schistosome Drug Discovery 7e5526209f02734f57ba19b0d17604ec 0000-0001-8580-1293 Gilda Padalino Gilda Padalino true false 2023-09-08 MEDS Schistosomiasis is one of the most important neglected tropical diseases. Until an effective vaccine is registered for use, the cornerstone of schistosomiasis control remains chemotherapy with praziquantel. The sustainability of this strategy is at substantial risk due to the possibility of praziquantel insensitive/resistant schistosomes developing. Considerable time and effort could be saved in the schistosome drug discovery pipeline if available functional genomics, bioinformatics, cheminformatics and phenotypic resources are systematically leveraged. Our approach, described here, outlines how schistosome-specific resources/methodologies, coupled to the open-access drug discovery database ChEMBL, can be cooperatively used to accelerate early-stage, schistosome drug discovery efforts. Our process identified seven compounds (fimepinostat, trichostatin A, NVP-BEP800, luminespib, epoxomicin, CGP60474 and staurosporine) with ex vivo anti-schistosomula potencies in the sub-micromolar range. Three of those compounds (epoxomicin, CGP60474 and staurosporine) also demonstrated potent and fast-acting ex vivo effects on adult schistosomes and completely inhibited egg production. ChEMBL toxicity data were also leveraged to provide further support for progressing CGP60474 (as well as luminespib and TAE684) as a novel anti-schistosomal compound. As very few compounds are currently at the advanced stages of the anti-schistosomal pipeline, our approaches highlight a strategy by which new chemical matter can be identified and quickly progressed through preclinical development. Journal Article Pharmaceutics 15 5 1359 MDPI AG 1999-4923 ChEMBL; schistosomiasis; drug discovery pipeline; schistosomula; adult worm; bioinformatics; cytotoxicity 28 4 2023 2023-04-28 10.3390/pharmaceutics15051359 http://dx.doi.org/10.3390/pharmaceutics15051359 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University This research was funded by the Wellcome Trust, grant number 107475/Z/15/Z. 2024-01-08T14:13:05.6811311 2023-09-08T15:56:05.8587393 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Pharmacy Gilda Padalino 0000-0001-8580-1293 1 Avril Coghlan 2 Giampaolo Pagliuca 3 Josephine E. Forde-Thomas 0000-0002-7202-3565 4 Matthew Berriman 0000-0002-9581-0377 5 Karl F. Hoffmann 6 64493__28710__0bd622d79e6d462e93a9d9bf1ee697de.pdf 64493.VOR.pdf 2023-10-05T09:30:48.7730596 Output 4917749 application/pdf Version of Record true © 2023 by the authors. Licensee MDPI, Basel, Switzerland. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0). true eng https://creativecommons.org/licenses/by/4.0/
title Using ChEMBL to Complement Schistosome Drug Discovery
spellingShingle Using ChEMBL to Complement Schistosome Drug Discovery
Gilda Padalino
title_short Using ChEMBL to Complement Schistosome Drug Discovery
title_full Using ChEMBL to Complement Schistosome Drug Discovery
title_fullStr Using ChEMBL to Complement Schistosome Drug Discovery
title_full_unstemmed Using ChEMBL to Complement Schistosome Drug Discovery
title_sort Using ChEMBL to Complement Schistosome Drug Discovery
author_id_str_mv 7e5526209f02734f57ba19b0d17604ec
author_id_fullname_str_mv 7e5526209f02734f57ba19b0d17604ec_***_Gilda Padalino
author Gilda Padalino
author2 Gilda Padalino
Avril Coghlan
Giampaolo Pagliuca
Josephine E. Forde-Thomas
Matthew Berriman
Karl F. Hoffmann
format Journal article
container_title Pharmaceutics
container_volume 15
container_issue 5
container_start_page 1359
publishDate 2023
institution Swansea University
issn 1999-4923
doi_str_mv 10.3390/pharmaceutics15051359
publisher MDPI AG
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Pharmacy{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Pharmacy
url http://dx.doi.org/10.3390/pharmaceutics15051359
document_store_str 1
active_str 0
description Schistosomiasis is one of the most important neglected tropical diseases. Until an effective vaccine is registered for use, the cornerstone of schistosomiasis control remains chemotherapy with praziquantel. The sustainability of this strategy is at substantial risk due to the possibility of praziquantel insensitive/resistant schistosomes developing. Considerable time and effort could be saved in the schistosome drug discovery pipeline if available functional genomics, bioinformatics, cheminformatics and phenotypic resources are systematically leveraged. Our approach, described here, outlines how schistosome-specific resources/methodologies, coupled to the open-access drug discovery database ChEMBL, can be cooperatively used to accelerate early-stage, schistosome drug discovery efforts. Our process identified seven compounds (fimepinostat, trichostatin A, NVP-BEP800, luminespib, epoxomicin, CGP60474 and staurosporine) with ex vivo anti-schistosomula potencies in the sub-micromolar range. Three of those compounds (epoxomicin, CGP60474 and staurosporine) also demonstrated potent and fast-acting ex vivo effects on adult schistosomes and completely inhibited egg production. ChEMBL toxicity data were also leveraged to provide further support for progressing CGP60474 (as well as luminespib and TAE684) as a novel anti-schistosomal compound. As very few compounds are currently at the advanced stages of the anti-schistosomal pipeline, our approaches highlight a strategy by which new chemical matter can be identified and quickly progressed through preclinical development.
published_date 2023-04-28T09:21:06Z
_version_ 1829003084308676608
score 11.058203

Similar Items